Table 2.
Regimen | Drug 1 | Drug 2 | Drug 3 |
---|---|---|---|
2 | S-1 (6.9 mg/kg, po, qd*14) | Oxaliplatin (5 mg/kg, ip, qw) | NA |
3 | Capecitabine (400 mg/kg, po, qd*14) | Oxaliplatin (5 mg/kg, ip, qw) | NA |
4 | Capecitabine (400 mg/kg, po, qd*14) | Oxaliplatin (5 mg/kg, ip, qw) | Epirubicin (5 mg/kg, ip, qw) |
5 | Cisplatin (5 mg/kg, ip, qw) | 5-FU (15 mg/kg, ip, qd*5) | Docetaxel (20 mg/kg, ip, qw) |
7 | Gemzar (60 mg/kg, ip, q4d) | Cisplatin (5 mg/kg, ip, qw) | NA |
12 | Oxaliplatin (5 mg/kg, ip, qw) | Irinotecan (40 mg/kg, ip, q4d) | NA |
Drug combinations used to test efficacy in PDX models, including detailed treatment conditions in brackets (); Combination regimens have the same numbering as Table 3
NA not available, po per os, ip intraperitoneal, qd once a day, biw twice a week, qw once a week, q4d once every 4 days